{"meshTags":["Thyroid Neoplasms","Protein Kinase Inhibitors","Antineoplastic Agents","Humans","Phenylurea Compounds","Clinical Trials as Topic","Angiogenesis Inhibitors","Protein Kinases","Quinolines","Animals"],"meshMinor":["Thyroid Neoplasms","Protein Kinase Inhibitors","Antineoplastic Agents","Humans","Phenylurea Compounds","Clinical Trials as Topic","Angiogenesis Inhibitors","Protein Kinases","Quinolines","Animals"],"publicationTypes":["Journal Article","Review"],"title":"[Preclinical and clinical researches of lenvatinib mesylate (Lenvima capsule), a novel antitumor agent approved for thyroid cancer treatment].","pubmedId":"26558314"}